Inclusion of ganglioside as the targeting ligand for human CD169+/SIGLEC-1+ APCs and TLR4 ligand MPLA in liposomes also resulted in cytokine production, robust tumor antigen cross-presentation, and tumor antigen-specific CD8+ T cell response activation, which confirmed another nanovaccine platform for enhancing anti-tumor immunotherapy [229]. This evidence concerns the gene SIGLEC1 and neoplasm.